University contributions to the HPV vaccine and implications for access to vaccines in developing countries: Addressing materials and know-how in university technology transfer policy

American Journal of Law and Medicine

Volumn 35, Issue 2-3, 2009, Pages 253-279

  Crager, Sara E ^a,b   Guillen, Ethan ^a,c   Price, Matt ^d  

^a YALE UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^d The College of William and Mary   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; WART VIRUS VACCINE;

ARTICLE; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; MORTALITY; PATENT; SOCIOECONOMICS; UNIVERSITY; UTERINE CERVIX TUMOR; VIROLOGY;

DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PAPILLOMAVIRUS VACCINES; PATENTS AS TOPIC; SOCIOECONOMIC FACTORS; UNIVERSITIES; UTERINE CERVICAL NEOPLASMS;

EID: 70249135290     PISSN: 00988588     EISSN: None     Source Type: Journal    
DOI: 10.1177/009885880903500202     Document Type: Article

References (107)

1. Executive Board, World Health Organization, Implementation of Resolutions: Progress Reports, 4 (Jan. 2, 2007) available at http://www.who.int/phi/Bl20-35-Addlen. pdf.
2. Id. at 4.
3. Id.
4. Id.
5. FIELDS IROLOGY 59 (David M. Knipe et al. eds., 5th ed. 2007).
6. Id. at 513.
7. Id. at 2302.
8. Id.
9. Id. at 513.
10. Id. at 2339.
11. Id.
12. Id.
13. Jian Zhou et al., Expression of Vaccinia Recombinant HPV Iff Ll and L2 ORF Proteins in Epithelial Cells is Sufficient for Assembly of HPV Virion-like Particles, 185 VIROLOGY 251, 251 (1991).
14. Shin-Je Ghim et al., HPV-1 Ll Protein Expressed in cos Cells Displays Conformational Epitopes Found on Intact Virions, 190 VIROLOGY 548, 548 (1992).
15. R. Kirnbauer et al., Papillomavirus Ll Major Capsid Protein Self-Assembles into Virus-Like Particles that are Highly Immunogenic, 89 PROC. NAT'L ACAD. SCI. USA 12180, 12180-84 (1992).
16. R. Kirnbauer et al., Efficient self-assembly of human papillomavirus type Iff Ll and L1-L2 into virus-like particles, 67 J. VIROL. 6929-36 (1993).
17. Id.
18. Id.
19. w Caroline McNeil, News, Who Invented the VLP Cervical Cancer Vaccines?, 98 J. NAT'L CANCER INST. 433, 433 (2006).
20. Id.
21. * to Protect Against Two Additional Cancers (Sept. 12, 2008) available at http://www.merck.com/newsroom/press-releases/product/2008-0925.html.
22. Janelle L. Grimes, HPV Vaccine Development: A Case Study of Prevention and Politics, 34 BIOCHEMISTRY & MOLECULAR BIOLOGY ED. 148, 151 (2006).
23. Event Brief, Merck, 4Q 2007 Merck & Co., Inc. Earnings Conference Call - Final (2007), available at http://insurancenewsnet.com/article.asp?n= l&neID=20080130560.2-l6e40cd824e653c3.
24. Transcript, Merck & Co. Inc. Q3 2008 Earnings Conference Call (Oct. 22, 2008) available at http://seekingalpha.com/article/l01228-merck-co-inc-q3- 2008-earningsconference-call-transcript?page=l.
25. Press Release, Merck, supra note 21.
26. Centers for Disease Control and Prevention, HPV Vaccine Information for Young Women, http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine-young-women. htm (last visited Apr. 2, 2009).
27. Centers for Disease Control and Prevention, CDC Vaccine Price List, http://www.cdc.gOv/vaccines/programs/vfc/cdc-vac-price-list.htm#pediatric (last visited Nov. 2008).
28. Jan M. Agosti & Sue J. Goldie, Introducing HPV Vaccine in Developing Countries - Key Challenges and Issues, 356 NEW ENG. J. MED. 1908, 1909 (2007).
29. April E. Effort & Ashley J. Stevens, Using Academic License Agreements to Promote Global Social Responsibility, 43 LES NOUVELLES: J. LICENSING EXECUTIVES SOC'Y 85, 87 (2008).
30. Jonathan J. Jensen et al., The Role of Public Sector Research in the Discovery of New Drugs, Poster at Annual Meeting, Association of University Technology Managers, San Francisco, CA, March 2007.
31. Id.
32. 3J ASS'N UNIV. TECH. MANAGERS, LICENSING SURVEY FY 2006 4 (2006).
33. GARETH WILLIAMS, JAMES ROBERTSON, & MIKE GILBERT, MARKS & CLERK BIOTECHNOLOGY REPORT 2007 (2007).
34. WORLD HEALTH ORG., Equitable Access to Essential Medicines: A Framework for Collective Action, in POLICY PERSPECTIVES ON MEDICINE 1 (2004).
35. White Paper, Cal. Inst. Tech. et al., In the Public Interest: Nine Points to Consider in Licensing University Technology, 1 (2007), available at http://otl.stanford.edu/industry/resources/whitepaper-10.pdf.
36. Id. at 8.
37. Ass'n Univ. Tech. Managers, Endorse the Nine Points to Consider, http://www.autm.net/source/NinePoints/ninepoints-endorsement.cfm (Apr. 3, 2008).
38. Andreas Billich, HPV vaccine Medlmmune/GlaxoSmithKline, 4 CURRENT OPINION IN INVESTIGATIONAL DRUGS 210-13 (2003);
39. Grimes, supra note 22, at 2 (noting that Commonwealth Serum Laboratories, a commercial partner of the University of Queensland, retained the rights in Australia and New Zealand).
40. Amy Gardner, Drugmaker Assists in Pushing for Mandate for HPV Vaccination, WASH. POST, FEB. 11, 2007, at C05.
41. Agosti & Goldie, supra note 28, at 1909.
42. Stacie Bloom, News, Q & A with the man who can stop cervical cancer in its tracks, 115 J. CLINICAL INVESTIGATION 2587, 2587 (2005).
43. Id.
44. Letter from Robert Berdahl, President, American Association of Universities, to US Representatives Anna Eshoo and Joe Barton (June 10, 2008), www.aau.edu/WorkArea/showcontent.aspx?id=6l30.
45. Henry Grabowski, Outlook: Follow-on biologies: data exclusivity and the balance between innovation and competition, 7 NATURE REVIEWS DRUG DISCOVERY 479, 479-88 (2008).
46. Kevin Outterson & Aaron S. Kesselheim, Market-Based Licensing for HPV Vaccines in Developing Countries, 27 HEALTH AFFAIRS 130, 130-39 (2008).
47. U. S. Food and Drug Administration, Generic Competition and Drug Prices, (2006), available at http://www.fda.gov/cder/ogd/generic-competition. htm, (last visited Nov. 18, 2008).
48. Medecins Sans Frontieres, Untangling the Web of Price Reductions: A Pricing Guide for Developing Countries, available at http:// doctorswithoutborders.org/publications/reports/2005/untanglingthewebv8.pdf.
49. See, for example, Effort and Stevens for a discussion of licensing mechanisms that can achieve this end. One example provided by Effort and Stevens achieves this by altering the standard definition of "patent rights" in the licensing terms to include follow-on patents for the purposes of executing the universities access policy. Effort & Stevens, supra note 29, at 85-101. For a discussion of capturing future improvements through a grant-back mechanism
50. see, Amy Kapczynski et al, Addressing Global Health Inequities: An Open-Licensing Approach for University Innovations, 20 BERKELEY TECH. L. J. 1031 (2005).
51. World Health Organization, World Health Statistics 2008, available at http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf.
52. Jill Ann Tarzian Sorensen & Donald A. Chambers, Evaluating Academic Technology Transfer Performance by How Well Access to Knowledge if Facilitated-Defining an Access Metric, 33 J. TECH. TRANSFER 534, 541-43 (2007).
53. The annual survey by the Association of University Technology Managers (AUTM) (one of the largest systematic surveys of university technology transfer activity), for instance, only measures metrics such as the number of patents, licenses executed and revenues received from licensing activity. The Association of University Technology Managers, http://www.autm.net/surveys/(last visited Mar. 30, 2009).
54. The Better World Project, also led by AUTM, offers vignettes on university technology transfer activities that have helped society but there is no related, systematically collected data. The Better World Project, http://www.betterworldproject.net/reports.cfm (last visited Mar. 30, 2009).
55. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984).
56. S. D. Roger & D. Goldsmith, Biosimilars: it's not as simple as cost alone, 33 J. CLINICAL PHARMACY & THERAPEUTICS 459, 461 (2008).
57. M. Karpusas, A. Whitty, L. Runkel, & P. Hochman, The structure of human interferon-beta: implications for activity, 54 CELL AND MOLECULAR LIFE SCI. 1203, 1203-16 (1998).
58. JoAnn A. Suzich et al., Systemiclmmunization with Papillomavirus Ll Protein Completely Prevents the Development of Viral Mucosal Papillomas, 92 PROC NAT'L ACAD. SCI. USA 11553, 11553-57 (1995).
59. Kathryn J. Hofmann et al., Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-like Particles in Saccharomyces Cerevisiae, 209 VIROLOGY 506, 506-18 (1995).
60. Thijs J. Giezen et al., Safety-related Regulatory Actions for Biologicals Approved in the United States and the European Union, 300 JAMA 1887, 1887-96 (2008).
61. Michele Kessler et al., Immunogenicity of Biopharmaceuticals, 21 NEPHROL. DIALYSIS TRANSPLANT (Supp. 5) v9, v10-v11 (2006).
62. David M. Dudzinski & Aaron S. Kesselheim, Scientific and Legal Viability of Followon Protein Drugs, 358 JAMA 843, 845 (2008) (citing testimony of Dr. William Hancock, at a hearing before the Senate Committee on the Judiciary, June 23, 2004, available at http://judiciary.senate.gov/hearings/ testimony.cfm?id=1239&wit-id=3625 (last visited Nov. 17, 2008)).
63. PA. Patten & H. Schellekens, The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development, 112 DEV. BIOL. 81-97 (2003).
64. A. Covie & M. K. Kuhlmann, Biosimiliars: Recent Developments, 39 INT. UROL. NEPHROL. 261, 262 (2007).
65. Sabine Louet, Lessons from Eprex for Biogenetic Firms, 21 NATURE BIOTECHNOLOGY 956, 956-57 (2003).
66. T. A. Neumann & M. Foote, Megakaryocyte Growth and Development Factor (MGDF) : An Mpl Ligand and Cytokine That Regulates Thrombopoiesi, 6 CYTOKINES, CELLULAR & MOLECULAR THERAPY 47, 47-56 (2000).
67. Robert S. Lowe et al., Human Papillomavirus Type 11 (HPV-11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like Particles Expressed in Yeast, 176 J. INFECTIOUS DISEASES 1141, 1144-45 (1997);
68. Kathrin U. Jansen et al., Vaccination with Yeast-expressed Cottontail Rabbit Papillomavirus (CRPV) Virus-like Particles Protects Rabbits from CRPV-induced Papilloma Formation, 13 VACCINE 1509, 1509-13 (1995).
69. Suzich, supra note 55, at 115555.
70. Dennis Dias et al., Optimization and Validation of a Multiplexed Luminex Assay to Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18, 12 CLIN. DIAGN. LAB. IMMUNOL. 959, 959-69 (2005);
71. Luisa L. Villa et al., Immunologic Responses Following Administration of a Vaccine Targeting Human Papillomavirus Types 6, 11, 16, and 18, 24 VACCINE 5571, 5580-83 (2006).
72. Ian Frazer, Correlating Immunity with Protection for HPV Infection, INT. J INFECT. IS. S10, S12 (2007).
73. Margaret Stanley et al., Prophylactic HPV Vaccines: Underlying Mechanisms, 24 VACCINE (Supp. 3) S3/106, S3/108 (2006).
74. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Oncology Drug Products, FDA Licenses Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil) for the Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus (2007), http://www.fda.gov/cder/offices/oodp/whatsnew/gardasil. htm (last visited Apr. 14, 2009).
75. Universities Allied for Essential Medicines, Model Provisions for an 'Equitable Access and Neglected Disease License" Version 1.0, http://www.essentialmedicine.org/EAL.pdf (last visited Apr. 2, 2009).
76. Samantha Chaifetz et al., Closing the Access Gap for Health Innovations: An Open Licensing Proposal for Universities, 3 GLOBALIZATION FC HEALTH 4 (2007), available at http://www.globalizationandhealth.eom/content/3/l/2.
77. See Kapczynski et al, supra note 48, at 1090-91 (describing the self-monitoring system in the EAL proposal).
78. Knowledge Ecology International, The Essential Medical Inventions Licensing Agency, http://www.keionline.org/misc-docs/emila.pdf (last visited Apr. 2, 2009) (hereafter "EMILA").
79. Effort & Stevens, supra note 29, at 90.
80. See Kapczynski et al, supra note 48;
81. EMILA, supra note 73.
82. Id.
83. U. S. Food and Drug Administration - Office of Generic Drugs Generic Competition and Drug Prices (2006), http://www.fda.gov/cder/ogd/generic- competition. htm (last visited April 3, 2009);
84. th ed. 2007), http://www.msf.org/source/access/2007/Untangling-the- Web-10th-ed-2007-pdf (last visited Apr. 4, 2009) (graphing the drop in price for specific drugs after generic drug competition).
85. Gunjan Pradhan Sinha, Shantha Developing $15 Cervical Cancer Vaccine, THE ECON. TIMES, Oct. 16, 2007, http://economictimes.indiatimes.com/ News/News-By-Industry/Shantha-developing-15-cer vical-cancer-vaccine/ articleshow/246l640.cms (last visited Apr. 4, 2009).
86. Sarah E. Frew et al., The Role of the Domestic Private Sector in Developing Countries for Addressing Local Health Needs, 8 INT. J. BIOTECHNOLOGY 91, 100 (2006).
87. Julie B. Milstien et al., Access to Vaccine Technologies in Developing Countries: Brazil and India, 25 VACCINE 7610, 7615 (2007)
88. (citing Boston Consulting Group, Global Vaccine Supply: The Changing Role of Suppliers, a Report Commissioned for GAVJ by WHO and the World Bank (2005)).
89. Id. at 7615, 7618.
90. Id. at 7614.
91. Frew et al., supra note 80, at 100.
92. See generally Carl Shapiro, Navigating the Patent Thicket: Cross Licenses, Patent Pools and Standard Setting, 1 INNOVATION POL'Y & THE ECON. 119 (2001) (discussing patent pools generally).
93. See generally Knowledge Ecology International, Patent Pools, http://www.keionline.org/index.php?option=com-content&task=view&id= 63&Itemid=l (last visited Apr. 4, 2009);
94. Doctors Without Borders/Medicins Sans Frontiers Campaign for Access to Essential Medicines, http://www.msfaccess.org/(last visited Apr. 4, 2009);
95. Essential Inventions, Essential Patent Pool for AIDS, http://www.essentialinventions.org/docs/eppa/(last visited Apr. 4, 2009).
96. Press Release, UNITAID, UNITAID Moves Toward a Patent Pool for Medicines (July 9, 2008), available at http://www.unitaid.eu/en/NEWS/UNITAID-moves- towards-apatent-pool-for-medicines.html.
97. Medical Innovation Prize Fund Act of 2007, S. 2210, 110th Cong. (2007).
98. See also Knowledge Ecology International, Prizes to Stimulate Innovation, http://www.keionline.org/index.php?option=com-content&task=view&id= 4&Itemid=l (compiling reports on the use of prize funds and patent pools to spur biomedical innovation while lowering medicine costs through generic production).
99. Knowledge Ecology International, Working Document - Barbados and Bolivia, Proposal 3, Priority Medicines and Vaccines Prize Fund (PMV/pf), at 2 (2008), http://www.keionline.org/misc-docs/b-b-igwg/prop3-pmv-pf.pdf.
100. Press Release, UNITAID, supra note 87.
101. Chaifetz et al., supra note 71, at 2
102. (citing Pharmaceutical Research and Manufacturers of America, Pharmaceutical Industry Profile 2005 - From Laboratory to Patient: Pathways to Biopharmaceutical Innovation (2005)).
103. Gregory K. Sobolski et al., Technology Licensing: Lessons from the US Experience, 294 JAMA 3137, 3138 (2005).
104. James Love, UNITAID Patent Pool at Mexico City AIDS Conference, KEI POLICY BLOG, August 6, 2008, http://www.keionline.org/index.php?option=com- jdwp&Itemid=39&p=135 (last visited Apr. 4, 2009). 93 See Kapczynski et al., supra note 48 (discussing the difficulties of expanding access requirements beyond patents).
105. Agosti & Goldie, supra note 28, at 1908-10.
106. World Health Org. [WHO], Sixty-First World Health Assem. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, WHA61.21, (May 24, 2008).
107. X PRIZE Foundation Press Release, X PRIZE Foundation to Help Fight Tuberculosis Worldwide with Gates Foundation Support, Oct. 16, 2008, http://www.xprize.org/foundation/press-release/x-prize-foundation-to-help- fighttuberculosis-worldwide-with-gates-foundati.